Ironwood Pharmaceuticals Inc (IRWD)
$3.53 -$0.04 (-1.26%) 4:38 PM 12/13/24
NASDAQ | $USD | Drug Manufacturers - Specialty & GenericStock Data
-
Market Cap
$548.90M -
Day's Range
$3.44 - $3.62 -
Volume
1,906,254 -
52 Week Low / High
$3.06 - $15.70 -
PE Ratio
- -
PEG Ratio
-0.26 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 3
- Strong Buy
- 2
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong Sell
- $16.50
- Target Price
Company News
-
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? — Oct 16th, 2024
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Ironwood Pharmaceuticals, Inc. (IRWD) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Re...
-
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? — Oct 16th, 2024
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Ironwood Pharmaceuticals, Inc. (IRWD) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Re...
-
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? — Oct 16th, 2024
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Ironwood Pharmaceuticals, Inc. (IRWD) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Re...
-
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... — Oct 9th, 2024
LINZESS Prescription Demand Growth: Increased 11% in Q2 2024. New-to-Brand Prescriptions Growth: Grew 15% year-over-year in Q2 2024. LINZESS US Net Sales: $211 million in Q2 2024. Ironwood Revenue: $94 million in Q2 2024, a decrease of 12% year-over-year. GAAP Net Loss: $1 million in Q2 20...
-
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? — Oct 16th, 2024
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Ironwood Pharmaceuticals, Inc. (IRWD) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Re...
-
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? — Oct 16th, 2024
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Ironwood Pharmaceuticals, Inc. (IRWD) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Re...
-
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... — Oct 9th, 2024
LINZESS Prescription Demand Growth: Increased 11% in Q2 2024. New-to-Brand Prescriptions Growth: Grew 15% year-over-year in Q2 2024. LINZESS US Net Sales: $211 million in Q2 2024. Ironwood Revenue: $94 million in Q2 2024, a decrease of 12% year-over-year. GAAP Net Loss: $1 million in Q2 20...
-
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... — Oct 9th, 2024
LINZESS Prescription Demand Growth: Increased 11% in Q2 2024. New-to-Brand Prescriptions Growth: Grew 15% year-over-year in Q2 2024. LINZESS US Net Sales: $211 million in Q2 2024. Ironwood Revenue: $94 million in Q2 2024, a decrease of 12% year-over-year. GAAP Net Loss: $1 million in Q2 20...
-
Ironwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025? — Sep 2nd, 2024
We recently compiled a list of the 10 Best Multibagger Penny Stocks of 2025.In this article, we are going to take a look at where Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) stands against the other multibagger penny stocks. What Are Multibagger Stocks And How To Identify Them The term ...
-
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... — Oct 9th, 2024
LINZESS Prescription Demand Growth: Increased 11% in Q2 2024. New-to-Brand Prescriptions Growth: Grew 15% year-over-year in Q2 2024. LINZESS US Net Sales: $211 million in Q2 2024. Ironwood Revenue: $94 million in Q2 2024, a decrease of 12% year-over-year. GAAP Net Loss: $1 million in Q2 20...
-
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? — Oct 16th, 2024
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Ironwood Pharmaceuticals, Inc. (IRWD) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Re...
-
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... — Oct 9th, 2024
LINZESS Prescription Demand Growth: Increased 11% in Q2 2024. New-to-Brand Prescriptions Growth: Grew 15% year-over-year in Q2 2024. LINZESS US Net Sales: $211 million in Q2 2024. Ironwood Revenue: $94 million in Q2 2024, a decrease of 12% year-over-year. GAAP Net Loss: $1 million in Q2 20...
-
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? — Oct 16th, 2024
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Ironwood Pharmaceuticals, Inc. (IRWD) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Re...
-
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... — Oct 9th, 2024
LINZESS Prescription Demand Growth: Increased 11% in Q2 2024. New-to-Brand Prescriptions Growth: Grew 15% year-over-year in Q2 2024. LINZESS US Net Sales: $211 million in Q2 2024. Ironwood Revenue: $94 million in Q2 2024, a decrease of 12% year-over-year. GAAP Net Loss: $1 million in Q2 20...
-
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... — Oct 9th, 2024
LINZESS Prescription Demand Growth: Increased 11% in Q2 2024. New-to-Brand Prescriptions Growth: Grew 15% year-over-year in Q2 2024. LINZESS US Net Sales: $211 million in Q2 2024. Ironwood Revenue: $94 million in Q2 2024, a decrease of 12% year-over-year. GAAP Net Loss: $1 million in Q2 20...
-
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... — Oct 9th, 2024
LINZESS Prescription Demand Growth: Increased 11% in Q2 2024. New-to-Brand Prescriptions Growth: Grew 15% year-over-year in Q2 2024. LINZESS US Net Sales: $211 million in Q2 2024. Ironwood Revenue: $94 million in Q2 2024, a decrease of 12% year-over-year. GAAP Net Loss: $1 million in Q2 20...
-
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? — Oct 16th, 2024
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Ironwood Pharmaceuticals, Inc. (IRWD) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Re...
Portfolio
Comprised of 1 portfolios